Science 20 January 1995: Vol. 267. no. 5196, pp. 381 - 383 DOI: 10.1126/science.7824936

Prev | Table of Contents | Next

Articles

Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B.

D Zenaty, Y Aigrain, M Peuchmaur, P Philippe-Chomette, C Baumann, F Cornelis, J P Hugot, D Chevenne, V Barbu, P J Guillausseau, et al. (2009)
Eur. J. Endocrinol. 160, 807-813
 |  Abstract »  |  Full Text »  |  PDF »

The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy.

G. H Sakorafas, H. Friess, and G. Peros (2008)
Endocr. Relat. Cancer 15, 871-884
 |  Abstract »  |  Full Text »  |  PDF »

A novel TNFRSF1A splice mutation associated with increased nuclear factor {kappa}appaB (NF-{kappa}B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS).

S M Churchman, L D Church, S Savic, L R Coulthard, B Hayward, B Nedjai, M D Turner, R J Mathews, E Baguley, G A Hitman, et al. (2008)
Ann Rheum Dis 67, 1589-1595
 |  Abstract »  |  Full Text »  |  PDF »

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

D. Hong, L. Ye, R. Gagel, L. Chintala, A. K. El Naggar, J. Wright, and R. Kurzrock (2008)
Mol. Cancer Ther. 7, 1001-1006
 |  Abstract »  |  Full Text »  |  PDF »

Synergistic Effect of Oncogenic RET and Loss of p18 on Medullary Thyroid Carcinoma Development.

W. van Veelen, C. J.R. van Gasteren, D. S. Acton, D. S. Franklin, R. Berger, C. J.M. Lips, and J. W.M. Hoppener (2008)
Cancer Res. 68, 1329-1337
 |  Abstract »  |  Full Text »  |  PDF »

Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study.

R. Elisei, B. Cosci, C. Romei, V. Bottici, G. Renzini, E. Molinaro, L. Agate, A. Vivaldi, P. Faviana, F. Basolo, et al. (2008)
J. Clin. Endocrinol. Metab. 93, 682-687
 |  Abstract »  |  Full Text »  |  PDF »

Hirschsprung disease, associated syndromes and genetics: a review.

J Amiel, E Sproat-Emison, M Garcia-Barcelo, F Lantieri, G Burzynski, S Borrego, A Pelet, S Arnold, X Miao, P Griseri, et al. (2008)
J. Med. Genet. 45, 1-14
 |  Abstract »  |  Full Text »  |  PDF »

Constitutive and AP20187-Induced Ret Activation in Photoreceptors Does Not Protect from Light-Induced Damage.

M. Allocca, U. Di Vicino, M. Petrillo, F. Carlomagno, L. Domenici, and A. Auricchio (2007)
Invest. Ophthalmol. Vis. Sci. 48, 5199-5206
 |  Abstract »  |  Full Text »  |  PDF »

Constitutive Ret Activity in Knock-In Multiple Endocrine Neoplasia Type B Mice Induces Profound Elevation of Brain Dopamine Concentration via Enhanced Synthesis and Increases the Number of TH-Positive Cells in the Substantia Nigra.

J. Mijatovic, M. Airavaara, A. Planken, P. Auvinen, A. Raasmaja, T. P. Piepponen, F. Costantini, L. Ahtee, and M. Saarma (2007)
J. Neurosci. 27, 4799-4809
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Mechanisms of RET Receptor-Mediated Oncogenesis in Multiple Endocrine Neoplasia 2B..

T. S. Gujral, V. K. Singh, Z. Jia, and L. M. Mulligan (2006)
Cancer Res. 66, 10741-10749
 |  Abstract »  |  Full Text »  |  PDF »

Engineering the Recruitment of Phosphotyrosine Binding Domain-containing Adaptor Proteins Reveals Distinct Roles for RET Receptor-mediated Cell Survival.

T. K. Lundgren, R. P. Scott, M. Smith, T. Pawson, and P. Ernfors (2006)
J. Biol. Chem. 281, 29886-29896
 |  Abstract »  |  Full Text »  |  PDF »

An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma..

D. Cordella, M. Muzza, L. Alberti, P. Colombo, P. Travaglini, P. Beck-Peccoz, L. Fugazzola, and L. Persani (2006)
Endocr. Relat. Cancer 13, 945-953
 |  Abstract »  |  Full Text »  |  PDF »

RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors.

J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra (2006)
Endocr. Rev. 27, 535-560
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Activating Mutation in the RET Tyrosine Kinase Domain Mediates Neoplastic Transformation.

A. Cranston, C. Carniti, S. Martin, P. Mondellini, Y. Hooks, J. Leyland, S. Hodgson, S. Clarke, M. Pierotti, B. A. J. Ponder, et al. (2006)
Mol. Endocrinol. 20, 1633-1643
 |  Abstract »  |  Full Text »  |  PDF »

The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins..

A. Iervolino, R. Iuliano, F. Trapasso, G. Viglietto, R. M. Melillo, F. Carlomagno, M. Santoro, and A. Fusco (2006)
Cancer Res. 66, 6280-6287
 |  Abstract »  |  Full Text »  |  PDF »

Mucocutaneous Neuromas: An Underrecognized Manifestation of PTEN Hamartoma-Tumor Syndrome..

J. V. Schaffer, H. Kamino, A. Witkiewicz, J. M. McNiff, and S. J. Orlow (2006)
Arch Dermatol 142, 625-632
 |  Abstract »  |  Full Text »  |  PDF »

The RetC620R Mutation Affects Renal and Enteric Development in a Mouse Model of Hirschsprung's Disease.

C. Carniti, S. Belluco, E. Riccardi, A. N. Cranston, P. Mondellini, B. A.J. Ponder, E. Scanziani, M. A. Pierotti, and I. Bongarzone (2006)
Am. J. Pathol. 168, 1262-1275
 |  Abstract »  |  Full Text »  |  PDF »

BAY 43-9006 inhibition of oncogenic RET mutants..

F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, and M. Santoro (2006)
J Natl Cancer Inst 98, 326-334
 |  Abstract »  |  Full Text »  |  PDF »

In Vivo and in Vitro Characterization of a Novel Germline RET Mutation Associated with Low-Penetrant Nonaggressive Familial Medullary Thyroid Carcinoma.

L. D'Aloiso, F. Carlomagno, M. Bisceglia, S. Anaganti, E. Ferretti, A. Verrienti, F. Arturi, D. Scarpelli, D. Russo, M. Santoro, et al. (2006)
J. Clin. Endocrinol. Metab. 91, 754-759
 |  Abstract »  |  Full Text »  |  PDF »

Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer.

C. J. Strock, J.-I. Park, D. M. Rosen, B. Ruggeri, S. R. Denmeade, D. W. Ball, and B. D. Nelkin (2006)
J. Clin. Endocrinol. Metab. 91, 79-84
 |  Abstract »  |  Full Text »  |  PDF »

Inducible Dimerization of RET Reveals a Specific AKT Deregulation in Oncogenic Signaling.

B. Freche, P. Guillaumot, J. Charmetant, L. Pelletier, C. Luquain, D. Christiansen, M. Billaud, and S. N. Manie (2005)
J. Biol. Chem. 280, 36584-36591
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of Protein Kinase B Tyrosine Phosphorylation by Thyroid-Specific Oncogenic RET/PTC Kinases.

H. S. Jung, D. W. Kim, Y. S. Jo, H. K. Chung, J. H. Song, J. S. Park, K. C. Park, S. H. Park, J. H. Hwang, K.-W. Jo, et al. (2005)
Mol. Endocrinol. 19, 2748-2759
 |  Abstract »  |  Full Text »  |  PDF »

A Drosophila Model of Multiple Endocrine Neoplasia Type 2.

R. D. Read, P. J. Goodfellow, E. R. Mardis, N. Novak, J. R. Armstrong, and R. L. Cagan (2005)
Genetics 171, 1057-1081
 |  Abstract »  |  Full Text »  |  PDF »

Src Homology-2-Containing Protein Tyrosine Phosphatase-1 Restrains Cell Proliferation in Human Medullary Thyroid Carcinoma.

M. C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, and E. C. degli Uberti (2005)
Endocrinology 146, 2692-2698
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors.

V. Papadimitrakopoulou, S. Agelaki, H. T. Tran, M. Kies, R. Gagel, R. Zinner, E. Kim, G. Ayers, J. Wright, and F. Khuri (2005)
Clin. Cancer Res. 11, 4151-4159
 |  Abstract »  |  Full Text »  |  PDF »

RET-Familial Medullary Thyroid Carcinoma Mutants Y791F and S891A Activate a Src/JAK/STAT3 Pathway, Independent of Glial Cell Line-Derived Neurotrophic Factor.

I. Plaza Menacho, R. Koster, A. M. van der Sloot, W. J. Quax, J. Osinga, T. van der Sluis, H. Hollema, G. M. Burzynski, O. Gimm, C. H.C.M. Buys, et al. (2005)
Cancer Res. 65, 1729-1737
 |  Abstract »  |  Full Text »  |  PDF »

Minireview: RET: Normal and Abnormal Functions.

M. Santoro, R. M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco (2004)
Endocrinology 145, 5448-5451
 |  Abstract »  |  Full Text »  |  PDF »

Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.

S Jindrichova, J Vcelak, P Vlcek, M Neradilova, J Nemec, and B Bendlova (2004)
J. Endocrinol. 183, 257-265
 |  Abstract »  |  Full Text »  |  PDF »

Central Role of the Threonine Residue within the p+1 Loop of Receptor Tyrosine Kinase in STAT3 Constitutive Phosphorylation in Metastatic Cancer Cells.

Z.-l. Yuan, Y.-j. Guan, L. Wang, W. Wei, A. B. Kane, and Y. E. Chin (2004)
Mol. Cell. Biol. 24, 9390-9400
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT1-Dependent Genes by RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinoma) Oncogenic Tyrosine Kinases.

E. S. Hwang, D. W. Kim, J. H. Hwang, H. S. Jung, J. M. Suh, Y. J. Park, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, et al. (2004)
Mol. Endocrinol. 18, 2672-2684
 |  Abstract »  |  Full Text »  |  PDF »

A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure.

G. Orgiana, G. Pinna, A. Camedda, V. De Falco, M. Santoro, R. M. Melillo, R. Elisei, C. Romei, S. Lai, C. Carcassi, et al. (2004)
J. Clin. Endocrinol. Metab. 89, 4810-4816
 |  Abstract »  |  Full Text »  |  PDF »

The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma.

R. M. Melillo, A. M. Cirafici, V. De Falco, M. Bellantoni, G. Chiappetta, A. Fusco, F. Carlomagno, A. Picascia, D. Tramontano, G. Tallini, et al. (2004)
Am. J. Pathol. 165, 511-521
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Point Mutation of the RET Protooncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma.

C. Jimenez, G. T. Dang, P. N. Schultz, A. El-Naggar, S. Shapiro, E. A. Barnes, D. B. Evans, R. Vassilopoulou-Sellin, R. F. Gagel, G. J. Cote, et al. (2004)
J. Clin. Endocrinol. Metab. 89, 3521-3526
 |  Abstract »  |  Full Text »  |  PDF »

Expression Profiles Provide Insights into Early Malignant Potential and Skeletal Abnormalities in Multiple Endocrine Neoplasia Type 2B Syndrome Tumors.

S. Jain, M. A. Watson, M. K. DeBenedetti, Y. Hiraki, J. F. Moley, and J. Milbrandt (2004)
Cancer Res. 64, 3907-3913
 |  Abstract »  |  Full Text »  |  PDF »

Biological Effects of the Dual Phenotypic Janus Mutation of ret Cosegregating with Both Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease.

E. Arighi, A. Popsueva, D. Degl'Innocenti, M. G. Borrello, C. Carniti, N. M. Perala, M. A. Pierotti, and H. Sariola (2004)
Mol. Endocrinol. 18, 1004-1017
 |  Abstract »  |  Full Text »  |  PDF »

A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas.

G. M. Pierantoni, S. Battista, F. Pentimalli, M. Fedele, R. Visone, A. Federico, M. Santoro, G. Viglietto, and A. Fusco (2003)
Carcinogenesis 24, 1861-1869
 |  Abstract »  |  Full Text »  |  PDF »

Germline Succinate Dehydrogenase Subunit D Mutation Segregating with Familial Non-RET C Cell Hyperplasia.

J. Lima, J. Teixeira-Gomes, P. Soares, V. Maximo, M. Honavar, D. Williams, and M. Sobrinho-Simoes (2003)
J. Clin. Endocrinol. Metab. 88, 4932-4937
 |  Abstract »  |  Full Text »  |  PDF »

The Tyrosine Phosphatase Shp-2 Mediates Intracellular Signaling Initiated by Ret Mutants.

A. D'Alessio, D. Califano, M. Incoronato, G. Santelli, T. Florio, G. Schettini, M. S. Carlomagno, L. Cerchia, and V. de Franciscis (2003)
Endocrinology 144, 4298-4305
 |  Abstract »  |  Full Text »  |  PDF »

CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth.

C. J. Strock, J.-I. Park, M. Rosen, C. Dionne, B. Ruggeri, S. Jones-Bolin, S. R. Denmeade, D. W. Ball, and B. D. Nelkin (2003)
Cancer Res. 63, 5559-5563
 |  Abstract »  |  Full Text »  |  PDF »

Single nucleotide polymorphic alleles in the 5' region of the RET proto-oncogene define a risk haplotype in Hirschsprung's disease.

M Sancandi, P Griseri, B Pesce, G Patrone, F Puppo, M Lerone, G Martucciello, G Romeo, R Ravazzolo, M Devoto, et al. (2003)
J. Med. Genet. 40, 714-718
 |  Full Text »  |  PDF »

Pheochromocytoma: The Expanding Genetic Differential Diagnosis.

J. Bryant, J. Farmer, L. J. Kessler, R. R. Townsend, and K. L. Nathanson (2003)
J Natl Cancer Inst 95, 1196-1204
 |  Abstract »  |  Full Text »  |  PDF »

RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinomas) Tyrosine Kinase Phosphorylates and Activates Phosphoinositide-Dependent Kinase 1 (PDK1): An Alternative Phosphatidylinositol 3-Kinase-Independent Pathway to Activate PDK1.

D. W. Kim, J. H. Hwang, J. M. Suh, H. Kim, J. H. Song, E. S. Hwang, I. Y. Hwang, K. C. Park, H. K. Chung, J. M. Kim, et al. (2003)
Mol. Endocrinol. 17, 1382-1394
 |  Abstract »  |  Full Text »  |  PDF »

RET Codon 634 Mutations in Multiple Endocrine Neoplasia Type 2: Variable Clinical Features and Clinical Outcome.

M. K. Punales, H. Graf, J. L. Gross, and A. L. Maia (2003)
J. Clin. Endocrinol. Metab. 88, 2644-2649
 |  Abstract »  |  Full Text »  |  PDF »

Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region.

P. M. Chan, S. Ilangumaran, J. La Rose, A. Chakrabartty, and R. Rottapel (2003)
Mol. Cell. Biol. 23, 3067-3078
 |  Abstract »  |  Full Text »  |  PDF »

PP1 Inhibitor Induces Degradation of RETMEN2A and RETMEN2B Oncoproteins through Proteosomal Targeting.

C. Carniti, C. Perego, P. Mondellini, M. A. Pierotti, and I. Bongarzone (2003)
Cancer Res. 63, 2234-2243
 |  Abstract »  |  Full Text »  |  PDF »

Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2).

F. Carlomagno, D. Vitagliano, T. Guida, F. Basolo, M. D. Castellone, R. M. Melillo, A. Fusco, and M. Santoro (2003)
J. Clin. Endocrinol. Metab. 88, 1897-1902
 |  Abstract »  |  Full Text »  |  PDF »

Multiple Endocrine Neoplasia Type 2: Evaluation of the Genotype-Phenotype Relationship.

L. Yip, G. J. Cote, S. E. Shapiro, G. D. Ayers, C. E. Herzog, R. V. Sellin, S. I. Sherman, R. F. Gagel, J. E. Lee, and D. B. Evans (2003)
Arch Surg 138, 409-416
 |  Abstract »  |  Full Text »  |  PDF »

ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases.

F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A. J. Ryan, G. Fontanini, A. Fusco, and M. Santoro (2002)
Cancer Res. 62, 7284-7290
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Val648Ile Substitution in RET Protooncogene Observed in a Cys634Arg Multiple Endocrine Neoplasia Type 2A Kindred Presenting with an Adrenocorticotropin-Producing Pheochromocytoma.

A. B. Nunes, M. C. L. Ezabella, A. C. Pereira, J. E. Krieger, and S. P. A. Toledo (2002)
J. Clin. Endocrinol. Metab. 87, 5658-5661
 |  Abstract »  |  Full Text »  |  PDF »

The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.

G. Pelicci, F. Troglio, A. Bodini, R. M. Melillo, V. Pettirossi, L. Coda, A. De Giuseppe, M. Santoro, and P. G. Pelicci (2002)
Mol. Cell. Biol. 22, 7351-7363
 |  Abstract »  |  Full Text »  |  PDF »

Role of Dok1 in Cell Signaling Mediated by RET Tyrosine Kinase.

H. Murakami, Y. Yamamura, Y. Shimono, K. Kawai, K. Kurokawa, and M. Takahashi (2002)
J. Biol. Chem. 277, 32781-32790
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of Gene Expression Induced by RET with MEN2A or MEN2B Mutation.

T. Watanabe, M. Ichihara, M. Hashimoto, K. Shimono, Y. Shimoyama, T. Nagasaka, Y. Murakumo, H. Murakami, H. Sugiura, H. Iwata, et al. (2002)
Am. J. Pathol. 161, 249-256
 |  Abstract »  |  Full Text »  |  PDF »

Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma : A Search for the Early Precursors of Papillary Cancer.

A. Fusco, G. Chiappetta, P. Hui, G. Garcia-Rostan, L. Golden, B. K. Kinder, D. A. Dillon, A. Giuliano, A. M. Cirafici, M. Santoro, et al. (2002)
Am. J. Pathol. 160, 2157-2167
 |  Abstract »  |  Full Text »  |  PDF »

Pheochromocytoma -- Death of an Axiom.

R. G. Dluhy (2002)
N. Engl. J. Med. 346, 1486-1488
 |  Full Text »  |  PDF »

The Kinase Inhibitor PP1 Blocks Tumorigenesis Induced by RET Oncogenes.

F. Carlomagno, D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, A. Fusco, A. Gazit, A. Levitzki, and M. Santoro (2002)
Cancer Res. 62, 1077-1082
 |  Abstract »  |  Full Text »  |  PDF »

RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors.

M. Santoro, M. Papotti, G. Chiappetta, G. Garcia-Rostan, M. Volante, C. Johnson, R. L. Camp, F. Pentimalli, C. Monaco, A. Herrero, et al. (2002)
J. Clin. Endocrinol. Metab. 87, 370-379
 |  Abstract »  |  Full Text »  |  PDF »

Hirschsprung disease, associated syndromes, and genetics: a review.

J. Amiel and S. Lyonnet (2001)
J. Med. Genet. 38, 729-739
 |  Abstract »  |  Full Text »  |  PDF »

The Sensitivity of Activated Cys Ret Mutants to Glial Cell Line-Derived Neurotrophic Factor Is Mandatory To Rescue Neuroectodermic Cells from Apoptosis.

B. Mograbi, R. Bocciardi, I. Bourget, T. Juhel, D. Farahi-Far, G. Romeo, I. Ceccherini, and B. Rossi (2001)
Mol. Cell. Biol. 21, 6719-6730
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Ret Oncogene Activity by the Protein Tyrosine Phosphatase SHP1.

A. M. Hennige, R. Lammers, W. Hoppner, D. Arlt, V. Strack, R. Teichmann, F. Machicao, A. Ullrich, H.-U. Haring, and M. Kellerer (2001)
Endocrinology 142, 4441-4447
 |  Abstract »  |  Full Text »  |  PDF »

Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the {beta}-Catenin Pathway.

A. Danilkovitch-Miagkova, A. Miagkov, A. Skeel, N. Nakaigawa, B. Zbar, and E. J. Leonard (2001)
Mol. Cell. Biol. 21, 5857-5868
 |  Abstract »  |  Full Text »  |  PDF »

Germline RET 634 Mutation Positive MEN 2A-related C-Cell Hyperplasias Have Genetic Features Consistent with Intraepithelial Neoplasia.

S. J. Diaz-Cano, M. de Miguel, A. Blanes, R. Tashjian, and H. J. Wolfe (2001)
J. Clin. Endocrinol. Metab. 86, 3948-3957
 |  Abstract »  |  Full Text »  |  PDF »

Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade.

R. M. Melillo, M. Santoro, S.-H. Ong, M. Billaud, A. Fusco, Y. R. Hadari, J. Schlessinger, and I. Lax (2001)
Mol. Cell. Biol. 21, 4177-4187
 |  Abstract »  |  Full Text »  |  PDF »

Nuclear Factor-{{kappa}}B Is Constitutively Active in C-Cell Carcinoma and Required for RET-induced Transformation.

L. Ludwig, H. Kessler, M. Wagner, C. Hoang-Vu, H. Dralle, G. Adler, B. O. Bohm, and R. M. Schmid (2001)
Cancer Res. 61, 4526-4535
 |  Abstract »  |  Full Text »  |  PDF »

Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical Properties.

A. Machens, O. Gimm, R. Hinze, W. Höppner, B. O. Boehm, and H. Dralle (2001)
J. Clin. Endocrinol. Metab. 86, 1104-1109
 |  Abstract »  |  Full Text »

Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B.

D. Salvatore, R. M. Melillo, C. Monaco, R. Visconti, G. Fenzi, G. Vecchio, A. Fusco, and M. Santoro (2001)
Cancer Res. 61, 1426-1431
 |  Abstract »  |  Full Text »

Loss of Heterozygosity at the RET Protooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A.

L. Quadro, O. Fattoruso, M. P. Cosma, U. Verga, A. Porcellini, A. Libroia, and V. Colantuoni (2001)
J. Clin. Endocrinol. Metab. 86, 239-244
 |  Abstract »  |  Full Text »

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

J. R Hansford and L. M Mulligan (2000)
J. Med. Genet. 37, 817-827
 |  Abstract »  |  Full Text »

Tyrosines 1015 and 1062 Are in VivoAutophosphorylation Sites in Ret and Ret-Derived Oncoproteins.

D. Salvatore, M. V. Barone, G. Salvatore, R. M. Melillo, G. Chiappetta, A. Mineo, G. Fenzi, G. Vecchio, A. Fusco, and M. Santoro (2000)
J. Clin. Endocrinol. Metab. 85, 3898-3907
 |  Abstract »  |  Full Text »

Rotational Coupling of the Transmembrane and Kinase Domains of the Neu Receptor Tyrosine Kinase.

C. A. Bell, J. A. Tynan, K. C. Hart, A. N. Meyer, S. C. Robertson, and D. J. Donoghue (2000)
Mol. Biol. Cell 11, 3589-3599
 |  Abstract »  |  Full Text »

Tissue-specific Carcinogenesis in Transgenic Mice Expressing the RET Proto-Oncogene with a Multiple Endocrine Neoplasia Type 2A Mutation.

K. Kawai, T. Iwashita, H. Murakami, N. Hiraiwa, A. Yoshiki, M. Kusakabe, K. Ono, K.-i. Iida, A. Nakayama, and M. Takahashi (2000)
Cancer Res. 60, 5254-5260
 |  Abstract »  |  Full Text »

Tyrosine 1062 of RET-MEN2A Mediates Activation of Akt (Protein Kinase B) and Mitogen-activated Protein Kinase Pathways Leading to PC12 Cell Survival.

Gabriella De Vita, R. M. Melillo, F. Carlomagno, R. Visconti, M. D. Castellone, A. Bellacosa, M. Billaud, A. Fusco, P. N. Tsichlis, and M. Santoro (2000)
Cancer Res. 60, 3727-3731
 |  Abstract »  |  Full Text »

Abrogation of Nerve Growth Factor-induced Terminal Differentiation by ret Oncogene Involves Perturbation of Nuclear Translocation of ERK.

G. L. Colucci-D'Amato, A. D'Alessio, D. Califano, G. Cali, C. Rizzo, L. Nitsch, G. Santelli, and V. de Franciscis (2000)
J. Biol. Chem. 275, 19306-19314
 |  Abstract »  |  Full Text »  |  PDF »

Large and diverse numbers of human diseases with HIKE mutations.

F. D. Ciccarelli, A. Acciarito, and S. Alberti (2000)
Hum. Mol. Genet. 9, 1001-1007
 |  Abstract »  |  Full Text »  |  PDF »

High Levels of Tyrosine Phosphorylated Proto-Ret in Sporadic Pheochromocytomas.

H. Le Hir, L. G. Colucci-D’Amato, N. Charlet-Berguerand, P.-F. Plouin, X. Bertagna, Vittorio de Franciscis, and C. Thermes (2000)
Cancer Res. 60, 1365-1370
 |  Abstract »  |  Full Text »

Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas.

L. Frederick, X.-Y. Wang, G. Eley, and C. D. James (2000)
Cancer Res. 60, 1383-1387
 |  Abstract »  |  Full Text »

Transforming Ability of MEN2A-RET Requires Activation of the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway.

C. Segouffin-Cariou and M. Billaud (2000)
J. Biol. Chem. 275, 3568-3576
 |  Abstract »  |  Full Text »  |  PDF »

The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans.

Z. Vajo, C. A. Francomano, and D. J. Wilkin (2000)
Endocr. Rev. 21, 23-39
 |  Abstract »  |  Full Text »

Ultraviolet Light Induces Redox Reaction-mediated Dimerization and Superactivation of Oncogenic Ret Tyrosine Kinases.

M. Kato, T. Iwashita, K. Takeda, A. A. Akhand, W. Liu, M. Yoshihara, N. Asai, H. Suzuki, M. Takahashi, and I. Nakashima (2000)
Mol. Biol. Cell 11, 93-101
 |  Abstract »  |  Full Text »

Sympathoadrenal Hyperplasia Causes Renal Malformations in RetMEN2B-Transgenic Mice.

C. Gestblom, D. A. Sweetser, B. Doggett, and R. P. Kapur (1999)
Am. J. Pathol. 155, 2167-2179
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Case of Multiple Endocrine Neoplasia Type 2A Associated with Two de Novo Mutations of the RETProtooncogene.

A. Tessitore, A. A. Sinisi, D. Pasquali, M. Cardone, D. Vitale, A. Bellastella, and V. Colantuoni (1999)
J. Clin. Endocrinol. Metab. 84, 3522-3527
 |  Abstract »  |  Full Text »  |  PDF »

The Role of Amino Acids Surrounding Tyrosine 1062 in Ret in Specific Binding of the Shc Phosphotyrosine-Binding Domain.

Y. Ishiguro, T. Iwashita, H. Murakami, N. Asai, K.-i. Iida, H. Goto, T. Hayakawa, and M. Takahashi (1999)
Endocrinology 140, 3992-3998
 |  Abstract »  |  Full Text »

Hammerhead Ribozyme-mediated Inactivation of Mutant RET in Medullary Thyroid Carcinoma.

R. Parthasarathy, G. J. Cote, and R. F. Gagel (1999)
Cancer Res. 59, 3911-3914
 |  Abstract »  |  Full Text »  |  PDF »

Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment.

V V Smith, C Eng, and P J Milla (1999)
Gut 45, 143-146
 |  Abstract »  |  Full Text »  |  PDF »

A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma.

P. Pigny, C. Bauters, J.-L. Wemeau, M. Lecomte Houcke, M. Crepin, P. Caron, S. Giraud, A. Calender, M.-P. Buisine, J.-P. Kerckaert, et al. (1999)
J. Clin. Endocrinol. Metab. 84, 1700-1704
 |  Abstract »  |  Full Text »

Ret-mediated Mitogenesis Requires Src Kinase Activity.

R. M. Melillo, M. V. Barone, G. Lupoli, A. M. Cirafici, F. Carlomagno, R. Visconti, B. Matoskova, P. P. Di Fiore, G. Vecchio, A. Fusco, et al. (1999)
Cancer Res. 59, 1120-1126
 |  Abstract »  |  Full Text »  |  PDF »

Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development.

S Srinivas, Z Wu, C. Chen, V D'Agati, and F Costantini (1999)
Development 126, 1375-1386
 |  Abstract »  |  PDF »

RET Proto-Oncogene in the Development of Human Cancer.

C. Eng (1999)
J. Clin. Oncol. 17, 380
 |  Abstract »  |  Full Text »  |  PDF »

An Activating Mutation in the Kit Receptor Abolishes the Stroma Requirement for Growth of ELM Erythroleukemia Cells, But Does Not Prevent Their Differentiation in Response to Erythropoietin.

N. R. Leslie, J. O'Prey, C. Bartholomew, and P. R. Harrison (1998)
Blood 92, 4798-4807
 |  Abstract »  |  Full Text »  |  PDF »

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

A. Bardelli, P. Longati, D. Gramaglia, C. Basilico, L. Tamagnone, S. Giordano, D. Ballinari, P. Michieli, and P. M. Comoglio (1998)
PNAS 95, 14379-14383
 |  Abstract »  |  Full Text »  |  PDF »

Oncological implications of RET gene mutations in Hirschsprung's disease.

R H Sijmons, R M W Hofstra, F A Wijburg, T P Links, R P Zwierstra, A Vermey, D C Aronson, G Tan-Sindhunata, G J Brouwers-Smalbraak, S M Maas, et al. (1998)
Gut 43, 542-547
 |  Abstract »  |  Full Text »  |  PDF »

Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprung's Disease.

F. Carlomagno, R. M. Melillo, R. Visconti, G. Salvatore, G. De Vita, G. Lupoli, Y. Yu, S. Jing, G. Vecchio, A. Fusco, et al. (1998)
Endocrinology 139, 3613-3619
 |  Abstract »  |  Full Text »  |  PDF »

Mutations in the Extracellular Domain Cause RET Loss of Function by a Dominant Negative Mechanism.

M. P. Cosma, M. Cardone, F. Carlomagno, and V. Colantuoni (1998)
Mol. Cell. Biol. 18, 3321-3329
 |  Abstract »  |  Full Text »

Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain.

S. C. Robertson, A. N. Meyer, K. C. Hart, B. D. Galvin, M. K. Webster, and D. J. Donoghue (1998)
PNAS 95, 4567-4572
 |  Abstract »  |  Full Text »  |  PDF »

Signal Transduction Pathways Activated by RET Oncoproteins in PC12 Pheochromocytoma Cells.

S. Xing, T. L. Furminger, Q. Tong, and S. M. Jhiang (1998)
J. Biol. Chem. 273, 4909-4914
 |  Abstract »  |  Full Text »  |  PDF »

Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene.

I. Schuffenecker, M. Virally-Monod, R. Brohet, D. Goldgar, B. Conte-Devolx, L. Leclerc, O. Chabre, A. Boneu, J. Caron, C. Houdent, et al. (1998)
J. Clin. Endocrinol. Metab. 83, 487-491
 |  Abstract »  |  Full Text »

GFRalpha -2 and GFRalpha -3 Are Two New Receptors for Ligands of the GDNF Family.

S. Jing, Y. Yu, M. Fang, Z. Hu, P. L. Holst, T. Boone, J. Delaney, H. Schultz, R. Zhou, and G. M. Fox (1997)
J. Biol. Chem. 272, 33111-33117
 |  Abstract »  |  Full Text »  |  PDF »

Activating mutations for the Met tyrosine kinase receptor in human cancer.

M. Jeffers, L. Schmidt, N. Nakaigawa, C. P. Webb, G. Weirich, T. Kishida, B. Zbar, and G. F. Vande Woude (1997)
PNAS 94, 11445-11450
 |  Abstract »  |  Full Text »  |  PDF »

Leucine Zipper-mediated Dimerization Is Essential for the PTC1 Oncogenic Activity.

Q. Tong, S. Xing, and S. M. Jhiang (1997)
J. Biol. Chem. 272, 9043-9047
 |  Abstract »  |  Full Text »  |  PDF »

Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

F.-M. Michiels, S. Chappuis, B. Caillou, A. Pasini, M. Talbot, R. Monier, G. M. Lenoir, J. Feunteun, and M. Billaud (1997)
PNAS 94, 3330-3335
 |  Abstract »  |  Full Text »  |  PDF »

Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential.

A. M. Cirafici, G. Salvatore, G. De Vita, F. Carlomagno, N. A. Dathan, R. Visconti, R. M. Melillo, A. Fusco, and M. Santoro (1997)
Endocrinology 138, 1450-1455
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products